Philips is planning to invest at least $150 million in new funding for its U.S. production base, including through the ...

Omeros’ efforts to get its transplant drug to market have already suffered one FDA rejection. | Omeros’ efforts to get its ...

Experienced business developer Derek Hicks has been handed the reins of Rezo Therapeutics, his first time at the helm of a ...

Evotec’s sweeping reorganization has claimed roughly 600 jobs since last March, 200 more than were originally planned under a ...

Shortly after welcoming a new CEO, robot developer Vicarious Surgical reported that it will be delaying the clinical trials ...

Blood oxygen tracking is returning to the Apple Watch after an 18-month hiatus, through a software update effective today.  | ...

Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G ...

Generation Bio is shedding 90% of its workforce after the biotech acknowledged it’s unlikely to find the cash to take its ...

Response Pharmaceuticals has shared phase 2 data in post-GLP-1 patients, linking its ex-Sanofi asset to reductions in ...

Oric Pharmaceuticals’ previously announced plan to focus resources on its two most advanced oncology drugs comes with a sting ...

Sarepta Therapeutics is selling off Arrowhead Pharmaceuticals’ shares to stretch its cash runway, while also inking a share ...

Vedanta Biosciences’ dreams of using live bacteria to treat inflammatory bowel disease (IBD) have been dashed. | Vedanta ...